LGM
AVBP icon

Logos Global Management’s ArriVent BioPharma AVBP Stock Holding History

Logos Global Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.7M Buy
1,000,000
+650,000
+186% +$19.2M 1.5% 23
2026
Q1 		$8.07M Buy
+350,000
New +$7.9M 0.4% 51

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Logos Global Management's AVBP Position: Q2 2026 in Review

Logos Global Management increased its ArriVent BioPharma (AVBP) stake by 186% in Q2 2026, buying an estimated $19.2M and bringing the position to 1,000,000 shares worth $34.7M. The position accounts for 1.5% of the portfolio, ranked #23.

Logos Global Management first reported a position in AVBP in Q1 2026 and has held it in 2 quarters since. 158 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Logos Global Management held 1,000,000 shares of ArriVent BioPharma worth $34.7M as of Q2 2026.
  • Logos Global Management bought 650,000 ArriVent BioPharma shares in Q2 2026, an estimated $19.2M.
  • ArriVent BioPharma made up 1.5% of Logos Global Management's portfolio in Q2 2026, its #23 holding.
  • Logos Global Management first reported a position in ArriVent BioPharma in Q1 2026 and has held it in 2 quarters since.
  • 158 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Logos Global Management's 13F filing for Q2 2026, filed 14 Aug 2026.